JPH10298093A - Liquid medicine for internal use - Google Patents
Liquid medicine for internal useInfo
- Publication number
- JPH10298093A JPH10298093A JP9121788A JP12178897A JPH10298093A JP H10298093 A JPH10298093 A JP H10298093A JP 9121788 A JP9121788 A JP 9121788A JP 12178897 A JP12178897 A JP 12178897A JP H10298093 A JPH10298093 A JP H10298093A
- Authority
- JP
- Japan
- Prior art keywords
- ingredient
- component
- group
- internal use
- function
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は内用液剤に関し、更
に詳細には抗疲労作用、抗ストレス作用、滋養強壮作用
を有する内用液剤に係わる。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a liquid preparation for internal use, and more particularly to a liquid preparation for internal use having an anti-fatigue action, an anti-stress action, and a nourishing tonic action.
【０００２】[0002]
【従来の技術】従来、抗疲労作用、抗ストレス作用、滋
養強壮作用を目的とする数種〜数１０種の生薬が配合さ
れた内用液剤が飲用されてきた。2. Description of the Related Art Conventionally, an internal liquid formulation containing several to several tens of crude drugs for the purpose of anti-fatigue action, anti-stress action, and nutritional tonic action has been drunk.
【０００３】[0003]
【発明が解決しようとする課題】しかし、他の医薬品と
異なり、抗疲労作用、抗ストレス作用、滋養強壮作用に
ついてどの程度の効果を有するかが明らかでないものが
多かった。尚、人参、インヨカク、ニクジュヨウなどの
生薬については、これらが強壮効果を有していること
は、薬理学的に証明されている。However, unlike other pharmaceuticals, it is not clear what effect the anti-fatigue action, anti-stress action, and nutritional tonic effect have. In addition, it has been pharmacologically proven that crude drugs such as ginseng, inyokaku and citrus have a tonic effect.
【０００４】そして従来の内用液剤でも特に１回の飲用
量が１００ｍｌ以下の少ない容量のドリンク剤或いはミ
ニドリンク剤と称される内用液剤では、期待される充分
な効果を得られる成分の配合組み合わせを発見すること
は困難であり、またその証明と根拠も不充分であった。
このため、抗疲労作用、抗ストレス作用、滋養強壮作用
について確実な効果を得られる成分の配合組み合わせの
究明が要望されていた。[0004] Even in the conventional liquid preparations, especially in the case of a small-volume drink preparation or a mini-drink preparation in which a single dose is 100 ml or less, the combination of components which can provide the expected sufficient effect is obtained. The combination was difficult to find, and its proof and grounds were inadequate.
For this reason, it has been desired to find a combination of components that can provide a certain effect on the anti-fatigue action, the anti-stress action, and the nutritional tonic effect.
【０００５】そこで本発明者は鋭意研究を重ねた結果、
肝機能改善作用を有する成分と、心機能改善作用を有す
る成分と、身体調整機能を有する成分とを組み合わせる
ことにより、確実に従来処方よりも抗疲労作用、抗スト
レス作用、滋養強壮作用が高まることを見いだし、本発
明の完成をみるに至ったものである。[0005] The inventor of the present invention has conducted intensive studies, and as a result,
Combination of a component having a liver function improving effect, a component having a cardiac function improving effect, and a component having a physical adjustment function ensures that the anti-fatigue effect, the anti-stress effect, and the nutritional tonic effect are higher than those of the conventional prescription. Have been completed, and the present invention has been completed.
【０００６】また更に、前記配合成分に特定の強壮生薬
を加えると、前記配合成分による効果が一段と高まるこ
とも見いだした。Further, it has been found that when a specific tonic crude drug is added to the above-mentioned components, the effect of the above-mentioned components is further enhanced.
【０００７】[0007]
【課題を解決するための手段】而して、本発明の要旨と
するところは、肝機能改善作用を有する成分、心機能改
善作用を有する成分及び身体調整機能を有する成分を含
むことを特徴とする内用液剤にある。Means for Solving the Problems The gist of the present invention is to include a component having a liver function improving effect, a component having a cardiac function improving effect, and a component having a physical adjustment function. In the liquid for internal use.
【０００８】また、前記肝機能改善作用を有する成分と
しては、グルクロノラクトン、甘草、クコシの群から選
択される一種又は複数種が、また心機能改善作用を有す
る成分としては、セイヨウサンザシ、ゴオウチンキ、ジ
オウの群から選択される一種又は複数種が、更にまた身
体調整機能を有する成分としては、エゾウコギ、トウジ
ン、トウキ、ブクリョウの群から選択される一種又は複
数種が用いられる。[0008] The component having the function of improving liver function may be one or more selected from the group consisting of glucuronolactone, licorice, and kokushi. , And one or more selected from the group of elephant, and as the component having a physical adjustment function, one or more selected from the group of eleuthero, eucalypt, touki, and bukuro are used.
【０００９】また、前記肝機能改善作用を有する成分、
心機能改善作用を有する成分並びに身体調整機能を有す
る成分に強壮生薬を加えてもよく、この場合には前記配
合成分による効果を一段と高めることができる。[0009] Further, the component having the liver function improving action,
Tonic crude drugs may be added to a component having a cardiac function improving effect and a component having a physical adjustment function, and in this case, the effect of the compounding component can be further enhanced.
【００１０】また、この強壮生薬としては、ロクジョ
ウ、オウセイ、タイサン、インヨウカク、シャクヤク、
ハンピ、ローヤルゼリーの群から選択される一種又は複
数種が用いられる。[0010] The tonic crude drugs include Rokujou, Ousei, Taisan, Inyokaku, Peonies,
One or more species selected from the group of hampi and royal jelly are used.
【００１１】尚、本発明に配合する生薬は、エキスであ
ることが好ましく、乾燥エキス、流エキスのいずれでも
よい。また、チンキであってもよい。The crude drug used in the present invention is preferably an extract, and may be either a dry extract or a fluid extract. Further, tincture may be used.
【００１２】また、本発明の内用液剤を製造するには、
日本薬局法製剤総則「液剤」の項に準じて製造し、濾
過、滅菌して製造する。In order to produce the liquid preparation for internal use of the present invention,
Manufactured according to the Japanese Pharmacopoeia General Rules for Pharmaceutical Preparations, "Liquids", filtered and sterilized.
【００１３】また、本発明の内用液剤には、前記成分の
他にビタミン（ビタミンＡ、Ｂ群、Ｃ、Ｄ、Ｅなど）、
カフェイン、タウリンなどを配合してもよい。The liquid preparation for internal use according to the present invention contains vitamins (vitamin A, group B, C, D, E, etc.),
Caffeine, taurine and the like may be blended.
【００１４】[0014]
【発明の効果】本発明は、前記の如く肝機能改善作用を
有する成分、心機能改善作用を有する成分並びに身体調
整機能を有する成分を含めた内用液剤であるから、確実
に従来処方よりも抗疲労作用、抗ストレス作用、滋養強
壮作用を高めることができる。As described above, the present invention is a liquid preparation for internal use containing a component having a liver function improving effect, a component having a cardiac function improving effect, and a component having a physical adjustment function as described above. It can enhance anti-fatigue, anti-stress and nourishing effects.
【００１５】また、前記配合成分に特定の強壮生薬を加
えた場合には、前記配合成分による効果を一段と高める
ことができる。[0015] Further, when a specific tonic crude drug is added to the blended component, the effect of the blended component can be further enhanced.
【００１６】[0016]
【実施例】以下、本発明の実施例及び試験例を示す。 実施例１ グルクロノラクトン（肝機能改善）・・・・・・・・・・１０００ｍｇ セイヨウサンザシ （心機能改善）・・・・・・・・・・・１５０ｍｇ ゴオウ （心機能改善）・・・・・・・・・・・・・３ｍｇ エゾウコギ （身体調整機能）・・・・・・・・・１０００ｍｇ ローヤルゼリー （強壮生薬）・・・・・・・・・・・・２００ｍｇ ロクジョウ （強壮生薬）・・・・・・・・・・・・・３０ｍｇ インヨウカク （強壮生薬）・・・・・・・・・・・ ３００ｍｇ ブクリョウ （強壮生薬）・・・・・・・・・・・・５００ｍｇ トウキ （強壮生薬）・・・・・・・・・・・・・６０ｍｇ シャクヤク （強壮生薬）・・・・・・・・・・・ １２０ｍｇ オウセイ （強壮生薬）・・・・・・・・・・・・９００ｍｇ ビタミンＢ２ （ビタミン）・・・・・・・・・・・・・１０ｍｇ ビタミンＢ６ （ビタミン）・・・・・・・・・・・・・１０ｍｇ ニコチン酸アミド・・・・・・・・・・・・・・・・・・・・５０ｍｇ イノシトール・・・・・・・・・・・・・・・・・・・・・１００ｍｇ 塩化カルニチン・・・・・・・・・・・・・・・・・・・ １００ｍｇ 無水カフェイン・・・・・・・・・・・・・・・・・・・・・５０ｍｇ 精製水 適 量 ───────────────────────────────── 全 量 ５０ｍｌ 上記成分、分量をとり、日本薬局法製剤総則「液剤」の
項に準じて製造し、濾過、滅菌して着色ガラス瓶に充填
した。EXAMPLES Examples and test examples of the present invention will be described below. Example 1 Glucuronolactone (Improvement of liver function) ... 1000 mg Hawthorn (Improvement of heart function) ... 150 mg Gooh (Improvement of heart function) ...・ ・ ・ ・ ・ ・ ・ ・ ・ ・ 3mg Eleuthero (Physical adjustment function) ・ ・ ・ ・ ・ ・ ・ ・ ・ 1000mg Royal jelly (Tonic crude drug) ・ ・ ・ ・ 200mg Rokujo (Tonic crude drug)・ ・ ・ ・ ・ ・ ・ ・ 30mg Inyokaku (tonicide) ・ ・ ・ 300mg Bakuryo (tonicide) ・ ・ ・ ・ 500mg Touki (Tonic crude drug) ··· 60 mg Peony (Tonic crude drug) ··· 120 mg Dust (Tonic crude drug) ········・ ・ 900mg Vitamin B2 (Vitamin 10mg Vitamin B6 (Vitamin) 10mg Nicotinamide ······· 50 mg inositol ········· 100 mg carnitine chloride ········· 100mg anhydrous caffeine 50mg purified water qs ──────────────── 50 ml in total volume Take the above components and amounts, manufacture according to the Japanese Pharmacopoeia Law for Pharmaceutical Preparations “Solutions,” filter, sterilize, and place in a colored glass bottle. Filled.
【００１７】 実施例２ グルクロノラクトン（肝機能改善）・・・・・・・・・・１０００ｍｇ セイヨウサンザシ （心機能改善）・・・・・・・・・・・１５０ｍｇ ゴオウ （心機能改善）・・・・・・・・・・・・・３ｍｇ エゾウコギ （身体調整機能）・・・・・・・・・・６００ｍｇ ローヤルゼリー （強壮生薬）・・・・・・・・・・・・１００ｍｇ ロクジョウ （強壮生薬）・・・・・・・・・・・・・１０ｍｇ トウキ （強壮生薬）・・・・・・・・・・・・・６０ｍｇ シャクヤク （強壮生薬）・・・・・・・・・・・・１２０ｍｇ オウセイ （強壮生薬）・・・・・・・・・・・・６００ｍｇ ビタミンＢ２ （ビタミン）・・・・・・・・・・・・・・５ｍｇ ビタミンＢ６ （ビタミン）・・・・・・・・・・・・・・５ｍｇ ニコチン酸アミド・・・・・・・・・・・・・・・・・・・・２０ｍｇ イノシトール・・・・・・・・・・・・・・・・・・・・・１００ｍｇ 塩化カルニチン・・・・・・・・・・・・・・・・・・・ １００ｍｇ 無水カフェイン・・・・・・・・・・・・・・・・・・・・・５０ｍｇ 精製水 適 量 ───────────────────────────────── 全 量 ５０ｍｌ 上記の処方を実施例１と同様にして調整した。Example 2 Glucuronolactone (Improvement of Liver Function) ····································································································································・ ・ ・ ・ ・ ・ ・ ・ 3mg Eleuthero (physical adjustment function) ・ ・ ・ ・ ・ ・ ・ ・ ・ 600mg Royal Jelly (Tonic crude drug) ・ ・ ・ ・ ・ 100mg (Tonic herbal medicine) ································································································· 60 mg・ ・ ・ ・ 120mg Dust (tonicide) ・ ・ ・ ・ 600mg Vitamin B2 (Vitamin) ・ ・ ・ ・ ・ ・ 5mg Vitamin B6 (Vitamin) ... 5mg d Formic acid amide 20 mg inositol 100 mg carnitine chloride ... 100mg anhydrous caffeine 50mg purified water ─────────────────────────────── Total volume 50 ml The above formulation was prepared in the same manner as in Example 1.
【００１８】 対象処方 ハンピチンキ・・・・・・・・・・・・・・・・・・・・・１００ｍｇ シベットチンキ・・・・・・・・・・・・・・・・・・・・２５０ｍｇ ゴオウチンキ・・・・・・・・・・・・・・・・・・・・・２５０ｍｇ ニンジン乾燥エキス・・・・・・・・・・・・・・・・・・・１０ｍｇ セイヨウサンザシエキス・・・・・・・・・・・・・・・・・・３ｍｇ ジオウ乾燥エキス・・・・・・・・・・・・・・・・・・・・３０ｍｇ ローヤルゼリー・・・・・・・・・・・・・・・・・・・・１００ｍｇ ビタミンＢ１・・・・・・・・・・・・・・・・・・・・・・１０ｍｇ ビタミンＢ２・・・・・・・・・・・・・・・・・・・・・・・５ｍｇ ビタミンＢ６・・・・・・・・・・・・・・・・・・・・・・１０ｍｇ ビタミンＢ１２・・・・・・・・・・・・・・・・・・・・・５０μｇ 酢酸トコフェロール・・・・・・・・・・・・・・・・・・・１０ｍｇ ニコチン酸アミド・・・・・・・・・・・・・・・・・・・・・５ｍｇ パントテニールアルコール・・・・・・・・・・・・・・・・１０ｍｇ コンドロイチン硫酸ナトリウム・・・・・・・・・・・・ １２０ｍｇ 無水カフェイン・・・・・・・・・・・・・・・・・・・・・５０ｍｇ 精製水 適 量 ───────────────────────────────── 全 量 ５０ｍｌTarget Formula Prescription tincture tincture 100 mg civet tincture 250mg carrot tincture ... 250mg carrot dried extract ... 10mg hawthorn extract ················· 3mg dried dried extract ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ 30mg Royal jelly ... 100mg Vitamin B1 ... 10mg Vitamin B2 ... ... 5mg Vitamin B6 ... 10m Vitamin B12 50 μg Tocopherol acetate 10 mg Nicotinamide 5mg pantothenyl alcohol 10mg sodium chondroitin sulfate・ ・ ・ ・ ・ ・ 120mg anhydrous caffeine ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ ・ 50mg Purified water qs ────────────── ─────────────────── Total volume 50ml
【００１９】試験例１ （検体） Ｇ−１；実施例１の液剤投与群 Ｇ−２；実施例２の液剤投与群 Ｔ−１；対象処方の液剤投与群 Ｃｏｎ；無処置群 （試験動物）体重２４±２ｇのｄｄｙ系マウスを１群１
０匹用いた。 （試験方法）１群１０匹のｄｄｙ系マウスをサンプル投
与前に５分間強制水泳させ、その直後に各検体０．１ｍ
ｌ／１０ｇ（体重）の割合で経口投与し、６０分経過後
に再度強制水泳を５分間行った。その際、マウスが水の
中で遊泳しない累計時間を測定した。 （試験結果）結果を図１に示したが、Ｇ−１及びＧ−
２、Ｔ−１はサンプル投与６０分後の強制水泳において
コントロール群（Ｃｏｎ）と比較して優位に強制水泳時
間を延長した。また、その延長時間は、Ｇ−１とＧ−２
を比較するとＧ−１の方が高い効果が認められ、どちら
の処方も対象処方より高い効果を得た。Test Example 1 (Specimen) G-1: Liquid-administered group of Example 1 G-2; Liquid-administered group of Example 2 T-1; Liquid-administered group Con of target formulation Con; No treatment group (test animal) Ddy mice weighing 24 ± 2 g / group 1
0 animals were used. (Test method) Each group of 10 ddy mice was forcibly swim for 5 minutes before sample administration, and immediately thereafter, each sample was 0.1 m in length.
Oral administration was performed at a rate of 1/10 g (body weight), and after 60 minutes, forced swimming was performed again for 5 minutes. At that time, the total time during which the mice did not swim in the water was measured. (Test Results) The results are shown in FIG.
2. T-1 significantly extended the forced swimming time in the forced swimming 60 minutes after the sample administration as compared to the control group (Con). The extension time is G-1 and G-2.
When G-1 was compared, G-1 showed a higher effect, and both formulations obtained higher effects than the target formulation.
【００２０】試験例２ （検体） Ｇ−１；実施例１の液剤投与群 Ｇ−２；実施例２の液剤投与群 Ｔ−１；対象処方の液剤投与群 Ｃｏｎ１；サンプル無処置群 Ｃｏｎ；無処置群 （試験動物）体重２４±２ｇのｄｄｙ系マウスを１群１
０匹用いた。 （試験方法）ストレス負荷薬剤としてテトラベナジン
（２００ｍｇ／ｋｇ ｉ．ｐ．）をマウスに投与し、投
与２４時間後に０．１ｍｌ／１０ｇ（体重）の割合で経
口投与し、１時間後に表面温度７５℃の熱板上にマウス
を置き、マウスが一定の方向に跳躍するように直径１０
ｃｍ、高さ４０ｃｍの透明プラスチック製円筒に入れ、
マウスが１分間に１５ｃｍ以上跳躍する回数を測定し
た。 （試験結果）結果を図２に示したが、Ｇ−１及びＧ−
２、Ｔ−１はテトラベナジン処置群コントロールと比較
して優位に跳躍回数を増加させたが、その増加の程度は
テトラベナジン無処置群コントロールにまでは及ばなか
った。また、処方１、２、対象処方の間には優位な差は
認められなかった。また、図３に示す如くマウスが１５
ｃｍ以上跳躍するまでに要した時間（潜時）の測定にお
いても同様にテトラベナジン無処置群コントロールまで
は及ばなかったが、テトラベナジン処置群コントロール
と比較して優位な差が認められた。Test Example 2 (Specimen) G-1: Liquid-administered group of Example 1 G-2; Liquid-administered group of Example 2 T-1; Liquid-administered group Con1 of target formulation; Sample untreated group Con; None Treatment group (test animals) ddy mice weighing 24 ± 2 g / group 1
0 animals were used. (Test method) Tetrabenazine (200 mg / kg ip) was administered to a mouse as a stress-loading agent, and was orally administered at a rate of 0.1 ml / 10 g (body weight) 24 hours after administration, and one hour later, the surface temperature was 75 ° C. Place the mouse on a hot plate with a diameter of 10 so that the mouse jumps in a certain direction.
cm, 40cm high in a transparent plastic cylinder,
The number of times the mouse jumped 15 cm or more per minute was measured. (Test Results) The results are shown in FIG.
2. T-1 significantly increased the number of jumps as compared to the tetrabenazine-treated group control, but the extent of the increase was not as great as that of the tetrabenazine-untreated group control. Also, no significant difference was observed between the prescriptions 1 and 2 and the target prescription. In addition, as shown in FIG.
Similarly, the measurement of the time (latency) required to jump more than 1 cm did not reach the control of the tetrabenazine-untreated group, but a significant difference was observed as compared with the tetrabenazine-treated group control.
【図１】縦軸に不動時間（秒）、横軸に各検体及びコン
トロール（Ｃｏｎ）を示した棒グラフである。FIG. 1 is a bar graph showing the immobility time (seconds) on the vertical axis and each sample and control (Con) on the horizontal axis.
【図２】縦軸に１分間の跳躍回数、横軸に各検体及びコ
ントロール（Ｃｏｎ）を示した棒グラフである。FIG. 2 is a bar graph showing the number of jumps per minute on the vertical axis and each sample and control (Con) on the horizontal axis.
【図３】縦軸に最初の跳躍までの時間（潜時）、横軸に
各検体及びコントロール（Ｃｏｎ）を示した棒グラフで
ある。FIG. 3 is a bar graph showing the time until the first jump (latency) on the vertical axis and each sample and control (Con) on the horizontal axis.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 ＦＩ Ａ６１Ｋ 35/64 Ａ６１Ｋ 35/64 35/84 35/84 Ａ ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 6 Identification code FI A61K 35/64 A61K 35/64 35/84 35/84 A
Claims (4)
善作用を有する成分及び身体調整機能を有する成分を含
むことを特徴とする内用液剤。1. A liquid preparation for internal use, comprising a component having a liver function improving effect, a component having a heart function improving effect, and a component having a physical adjustment function.
ロノラクトン、甘草、クコシの群から選択される一種又
は複数種、心機能改善作用を有する成分が、セイヨウサ
ンザシ、ゴオウチンキ、ジオウの群から選択される一種
又は複数種、身体調整機能を有する成分が、エゾウコ
ギ、トウジン、トウキ、ブクリョウの群から選択される
一種又は複数種である請求項１記載の内用液剤。2. The component having a liver function improving action is one or more selected from the group consisting of glucuronolactone, licorice, and kokushi, and the component having a heart function improving action is selected from the group of horseshoe hawthorn, giant tincture, and radish. 2. The liquid preparation for internal use according to claim 1, wherein the selected one or more kinds and the component having a physical adjustment function are one or more kinds selected from the group of Eleuthero, Toujin, Touki, Bukuryo.
用液剤。3. The liquid preparation for internal use according to claim 1, further comprising a tonic crude drug.
イサン、インヨウカク、シャクヤク、ハンピ、ローヤル
ゼリーの群から選択される一種又は複数種である請求項
３記載の内用液剤。4. The liquid preparation for internal use according to claim 3, wherein the tonic crude drug is one or more selected from the group consisting of Rokujo, Ousei, Taisan, Inyokaku, Peonies, Hampi, and Royal Jelly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9121788A JPH10298093A (en) | 1997-04-24 | 1997-04-24 | Liquid medicine for internal use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9121788A JPH10298093A (en) | 1997-04-24 | 1997-04-24 | Liquid medicine for internal use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH10298093A true JPH10298093A (en) | 1998-11-10 |
Family
ID=14819917
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9121788A Pending JPH10298093A (en) | 1997-04-24 | 1997-04-24 | Liquid medicine for internal use |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH10298093A (en) |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001240549A (en) * | 2000-03-01 | 2001-09-04 | Pola Chem Ind Inc | Immunopotentiator and composition containing the same |
| JP2001316279A (en) * | 2000-03-02 | 2001-11-13 | Pola Chem Ind Inc | Composition for fatigue recovery |
| KR20030020714A (en) * | 2001-09-04 | 2003-03-10 | (주)바이오뉴트리젠 | Composition for lowering blood lipid level comprising a lycium root extract |
| AT410399B (en) * | 1999-08-13 | 2003-04-25 | Red Bull Gmbh | Composition for reducing body fat or its formation comprising aqueous solution containing taurine, glucuronolactone, caffeine, sucrose, glucose, inositol and vitamins |
| JP2004182599A (en) * | 2001-12-18 | 2004-07-02 | Daicho Kikaku:Kk | Muscle-strengthening drug and antiinflammatory drug |
| JP2005104960A (en) * | 2003-09-12 | 2005-04-21 | Eisai Co Ltd | Internal liquid agent and taste quality change-preventing liquid agent for glucuronolactone-containing solution |
| WO2007077656A1 (en) * | 2005-12-28 | 2007-07-12 | Lion Corporation | Liquid medicine for internal use |
| JP2008162900A (en) * | 2006-12-27 | 2008-07-17 | Lion Corp | Liquid medicine composition for oral administration |
| JP2010215579A (en) * | 2009-03-18 | 2010-09-30 | Michiharu Sasaki | Hair nourishing liquid |
| JP2012149096A (en) * | 2001-12-18 | 2012-08-09 | Daicho Kikaku:Kk | Anti-inflammatory preparation |
| JP2013509395A (en) * | 2009-10-28 | 2013-03-14 | モデュテック エス．エー． | Preparations containing amino acids and plants and their activity in alcohol detoxification |
| CN102973685A (en) * | 2012-12-25 | 2013-03-20 | 刘国林 | Anti-fatigue traditional Chinese medicine preparation and preparation method thereof |
| CN103829343A (en) * | 2014-03-25 | 2014-06-04 | 印江土家族苗族自治县西园综合开发有限责任公司 | Peony seed and medlar oral solution and preparation process thereof |
| WO2014104162A1 (en) * | 2012-12-26 | 2014-07-03 | 興和株式会社 | Medicine |
| CN109157606A (en) * | 2018-07-09 | 2019-01-08 | 湖南神舟中药饮片有限公司 | A kind of preparation method of Chinese medicine radix polygonati officinalis medicine materical crude slice |
| JP2020158419A (en) * | 2019-03-26 | 2020-10-01 | 小林製薬株式会社 | Pharmaceutical composition for improving activity |
-
1997
- 1997-04-24 JP JP9121788A patent/JPH10298093A/en active Pending
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT410399B (en) * | 1999-08-13 | 2003-04-25 | Red Bull Gmbh | Composition for reducing body fat or its formation comprising aqueous solution containing taurine, glucuronolactone, caffeine, sucrose, glucose, inositol and vitamins |
| JP2001240549A (en) * | 2000-03-01 | 2001-09-04 | Pola Chem Ind Inc | Immunopotentiator and composition containing the same |
| JP2001316279A (en) * | 2000-03-02 | 2001-11-13 | Pola Chem Ind Inc | Composition for fatigue recovery |
| KR20030020714A (en) * | 2001-09-04 | 2003-03-10 | (주)바이오뉴트리젠 | Composition for lowering blood lipid level comprising a lycium root extract |
| JP2004182599A (en) * | 2001-12-18 | 2004-07-02 | Daicho Kikaku:Kk | Muscle-strengthening drug and antiinflammatory drug |
| JP2012149096A (en) * | 2001-12-18 | 2012-08-09 | Daicho Kikaku:Kk | Anti-inflammatory preparation |
| JP2005104960A (en) * | 2003-09-12 | 2005-04-21 | Eisai Co Ltd | Internal liquid agent and taste quality change-preventing liquid agent for glucuronolactone-containing solution |
| JP4694132B2 (en) * | 2003-09-12 | 2011-06-08 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Liquid for internal use and liquid for preventing change in taste of glucuronolactone-containing solution |
| JP5295571B2 (en) * | 2005-12-28 | 2013-09-18 | ライオン株式会社 | Solution for internal use for fatigue recovery |
| WO2007077656A1 (en) * | 2005-12-28 | 2007-07-12 | Lion Corporation | Liquid medicine for internal use |
| JP2008162900A (en) * | 2006-12-27 | 2008-07-17 | Lion Corp | Liquid medicine composition for oral administration |
| JP2010215579A (en) * | 2009-03-18 | 2010-09-30 | Michiharu Sasaki | Hair nourishing liquid |
| JP2013509395A (en) * | 2009-10-28 | 2013-03-14 | モデュテック エス．エー． | Preparations containing amino acids and plants and their activity in alcohol detoxification |
| CN102973685A (en) * | 2012-12-25 | 2013-03-20 | 刘国林 | Anti-fatigue traditional Chinese medicine preparation and preparation method thereof |
| WO2014104162A1 (en) * | 2012-12-26 | 2014-07-03 | 興和株式会社 | Medicine |
| JPWO2014104162A1 (en) * | 2012-12-26 | 2017-01-12 | 興和株式会社 | Medicine |
| CN103829343A (en) * | 2014-03-25 | 2014-06-04 | 印江土家族苗族自治县西园综合开发有限责任公司 | Peony seed and medlar oral solution and preparation process thereof |
| CN109157606A (en) * | 2018-07-09 | 2019-01-08 | 湖南神舟中药饮片有限公司 | A kind of preparation method of Chinese medicine radix polygonati officinalis medicine materical crude slice |
| JP2020158419A (en) * | 2019-03-26 | 2020-10-01 | 小林製薬株式会社 | Pharmaceutical composition for improving activity |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH10298093A (en) | Liquid medicine for internal use | |
| KR20070026422A (en) | Plant-based medicament for the treatment of hepatitis c | |
| ES2709633T3 (en) | Use of an extract of Ginkgo biloba leaves | |
| CN116096393A (en) | Composition of ginsenoside Rg3 and Rg5 and antitumor medicines thereof | |
| CN112972547A (en) | Traditional Chinese medicine composition for treating qi-blood deficiency syndrome and preparation method and application thereof | |
| CN102836340A (en) | Pharmaceutical composition for benefiting vital energy, enriching blood and nourishing liver and kidney as well as preparation method and application thereof | |
| US10821149B2 (en) | Composition and the use thereof | |
| CN106924406A (en) | A kind of pharmaceutical composition of adjuvant drug for treating AIDS and preparation method thereof | |
| JP2007008965A (en) | Hair growing agent | |
| CN101143202B (en) | Compound oral administration preparation with protective function to chemical liver injury | |
| CN108113962B (en) | Method for reducing astringency of traditional Chinese medicine oral preparation containing polyphenol | |
| JP3298214B2 (en) | Liquid for internal use | |
| JP2007161675A (en) | Fatigue-improving internal medicine | |
| JP2007016053A (en) | Antineoplastic agent | |
| CN106963777A (en) | A kind of preparation method and applications of " scutelloside jamaicin " compound | |
| KR930001926A (en) | Pharmaceutical composition for the treatment of mental and neurological disorders | |
| CN100435817C (en) | Medicine for treating rheumatism and rheumatoid diseases and preparing method | |
| JPH06128165A (en) | Cerebral function-improving agent | |
| CN105030716A (en) | Caffeine drug combination and preparation method thereof | |
| CN102058833B (en) | Traditional Chinese medicine composition-type spray or aerosol and preparation method thereof | |
| JP2001335500A (en) | Refreshment promoter | |
| CN101143203A (en) | Compound oral liquid with liver-protecting and stomach-nourishing function | |
| CN101518642B (en) | Oral liquid preparations | |
| CN107753567B (en) | Anti-fatigue pharmaceutical composition and preparation method and application thereof | |
| CN111358906A (en) | Traditional Chinese medicine composition suitable for exogenous diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20050120 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20050210 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20050210 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050906 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060106 |